Medical Students Articles

Med Student

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Raddatz D et al. – The data explain the frequent unresponsiveness of IBD to glucocorticoid treatment and suggest that alternative NFkB inhibition in IECs might be of use in IBD therapy. Drug development based on measuring anti–NFkB activity might be misleading and should therefore also include studies on relevant gene products.


   

Related Articles

IBD drugs and cancer risk
JAMA, 11/18/09    Relevance Score: 87%

Pediatric Inflammatory Bowel Disease: Highlighting Pediatric Differences in IBD
Gastroenterology Clinics of North America, 11/13/09    Relevance Score: 87%

Diagnostic Role and Clinical Association of ASCA and ANCA in Brazilian Patients with Inflammatory Bowel Disease
Digestive Diseases and Sciences, 10/19/09    Relevance Score: 87%

Safety Profile of IBD: Lymphoma Risks
Gastroenterology Clinics of North America, 11/23/09    Relevance Score: 85%

Safety Profile of IBD Therapeutics: Infectious Risks
Gastroenterology Clinics of North America, 11/19/09    Relevance Score: 85%

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address